

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
Under 37 CFR 1.97**

Docket No.  
**46639-57991**

In Re Application Of:

**Reubi, Jean-Claude**

Serial No.  
**10/626229**

Filing Date  
**July 24, 2003**

Examiner  
**Fetterolf, Brandon J.**

Group Art Unit  
**1642**

Title:

**Use of Labelled CCK-B Receptor Ligands for the Detection and Localization Of Malignant Human Tumors**

**Address to:**

**Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), and before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:


the statement specified in 37 CFR 1.97(e);

**OR**

the fee set forth in 37 CFR 1.17(p).

**37 CFR 1.97(d)**

3.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(c), and before the payment of the issue fee, and is accompanied by both the statement specified in 37 CFR 1.197(e), and the fee set forth in 37 CFR 1.17(p)



**Signature**

Dated:

**September 6, 2006**

Kevin M. Kercher, Reg. No. 33,408  
Thompson Coburn LLP  
One US Bank Plaza  
St. Louis, Missouri 63101  
314-552-6000  
314-552-7000 FAX

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10626229	
	Filing Date		2003-07-24	
	First Named Inventor		Reubi, Jean-Claude	
	Art Unit		1642	
	Examiner Name		Fetterolf, Brandon J.	
	Attorney Docket Number		46639-57991	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1						T <sup>5</sup>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>5</sup>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number	10626229
	Filing Date	2003-07-24
	First Named Inventor	Reubi, Jean-Claude
	Art Unit	1642
	Examiner Name	Fetterolf, Brandon J.
	Attorney Docket Number	46639-57991

1	REUBI, et al., Cholecystokinin(CCK)-A and CCK-B/Gastrin Receptors in Human Tumors, Institute of Pathology, University of Berne, Murtenstrasse 31, Berne, Switzerland, CH-3010, 1377-1386	<input type="checkbox"/>
2	MAILLEUX and VANDERHAEGHEN, Cholecystokinin receptors of A type in the human dorsal medulla oblongata and meningiomas, and of B type in small cell lung carcinomas, Neuroscience Letters, Elsevier Scientific Publishers Ireland Ltd., 1990, 117: 243-247	<input type="checkbox"/>
3	HRUBY, et al., Cholecystokinin analogues with high affinity and selectivity for brain membrane receptors, Int. J. Peptide Protein Res. 35, 1990, 556-573, Departments of Chemistry and Pharmacology, University of Arizona, Tucson, AZ, USA	<input type="checkbox"/>
4	REUBI, Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy, Endocrine Reviews 24(4): 389-427, Copyright 2003 by The Endocrine Society doi: 10.1210/er.2002-0007	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.